Background: Preclinical evidence from breast cancer cell lines and animal models suggest that aspirin could have anti-cancer properties. In a large breast cancer patient cohort, we investigated whether post-diagnostic low-dose aspirin use was associated with a reduction in the risk of breast cancer-specific mortality.
INTRODUCTION
Evidence from preclinical models support a potential role for aspirin in the prevention of cancer progression [1] . Aspirin acts by irreversibly inhibiting both PTSG (previously COX-1) and PTSG-2, resulting in a decrease in prostaglandin production [2] . Used at low dosage, aspirin is an anti-platelet agent, widely prescribed in the primary and secondary prevention of cardiovascular disease. Platelets are important in tumour cell migration [3] and experimental data have shown that aspirin can inhibit platelet-induced adhesion of circulating tumour cells [4] , and prevent metastases formation [5] . In breast cancer specifically, both in vitro and animal models demonstrate anti-angiogenic [6] and pro-apoptotic [7] effects for aspirin, as well as the suppression of tumour cell extravasation and tissue invasion [8] .
Results from some, but not all epidemiological studies suggest that aspirin use after cancer diagnosis may possibly increase survival and/or reduce cancer recurrence in breast cancer patients. Post-diagnostic aspirin use was associated with an approximate 47% reduction in breast cancer death among postmenopausal breast cancer patients enrolled in the Iowa Women's' Health Study [9] . Within the Nurses' Health Study, a more marked 64% reduction in breast cancer mortality risk was observed in users of aspirin after diagnosis [10] . These studies were, however, based on small numbers (e.g. 26 breast cancer deaths) [9] , used patient self-report of aspirin use (which may be subject to recall bias) [9, 10] and did not provide information on aspirin dose; therefore it is unclear whether the observed inverse associations are due to potential anti-platelet effects of aspirin. More recently, a study of 4,627 breast cancer patients resident in the Tayside area of Scotland reported a 58% reduction in breast cancer death associated with post-diagnostic low-dose aspirin use [11] . This particular analysis may have been partly affected by reverse causation [12] , such that the true association between aspirin and cancer-specific mortality may have been exaggerated if aspirin was withdrawn from cancer patients in whom death was suspected to be imminent [11] . In contrast to these findings, four other observational studies found little evidence of an association between aspirin use after diagnosis and breast cancer survival or recurrence [13] [14] [15] [16] [17] . A meta-analysis of 5 randomized controlled trials of low-dose aspirin to prevent vascular events showed that cancer patients (including patients with breast cancer) initiating aspirin treatment before cancer diagnosis had a reduced risk of metastasis and improved survival [18] . However, as these patients were taking aspirin before cancer diagnosis, it remains unclear whether low-dose aspirin use after cancer diagnosis, a time point more relevant for clinical intervention, confers any benefit.
Due to the inconsistencies and limitations of previous studies, we aimed to investigate whether post-diagnostic low-dose aspirin use was associated with a decreased risk of death from breast cancer in a large nation-wide cohort of breast cancer patients diagnosed in Scotland.
PATIENTS AND METHODS

Data sources
We conducted a retrospective cohort study which utilised linkages between national datasets from Scotland including the Scottish Cancer Registry (SMR06), the Prescribing Information System [19] , the General / Acute Inpatient and Day Case dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National Records of Scotland Death Records. 
Study population
We identified primary breast cancer patients (ICD code C50) diagnosed between January 
Study design
Exposure data
Low-dose aspirin dispensed in the community (identified from the Prescribing Information System) consisted of all medications in the low-dose aspirin section of the British National Formulary (BNF) [20] (Section 2.12). A quantity of 28 tablets was assumed for the less than 0.1% of prescriptions where quantity was assumed incorrect. Post-diagnostic low-dose aspirin use was investigated as a time varying covariate [21] (patients were initially considered non-users and then users after a lag of 6 months after their first low-dose aspirin prescription). The use of a lag is recommended [22] and in this study, removed prescriptions in the 6 month period prior to death as these may reflect end of life treatment (in sensitivity analyses, the duration of this lag was varied). Therefore, all patients had a minimum of 6 months potential exposure time after diagnosis. Analyses were conducted by increasing duration of low-dose aspirin use with individuals considered non-users prior to 6 months after first use, a short term user between 6 months after first use and 6 months after the 12 th prescription and a longer term user after this time.
Covariates
Data available from the Scottish Cancer Registry included AJCC cancer stage [23] , histological grade and surgery, chemotherapy and radiotherapy in the six months after diagnosis. Comorbidities that contribute to the Charlson index were determined prior to diagnosis based upon ICD10 diagnosis codes, as described previously [24] , in Scottish hospital inpatient (SMR01) and outpatient data (SMR00). A deprivation measure was determined using the 2009 Scottish Index of Multiple Deprivation based upon postcode of residence [25] . Statin use was determined from dispensing records and included in all adjusted analyses due to potential associations with breast cancer-specific outcomes after diagnosis [26] [27] [28] .
Statistical analysis
In the main analysis, time-dependent Cox regression models were used to calculate hazard ratios for breast cancer-specific death (HRs) and 95% confidence intervals (95% CIs) for post-diagnostic low-dose aspirin users compared with non-users using a time varying covariate as described previously. Adjusted analyses were conducted including the following potential confounders: sex, age, year of diagnosis, deprivation, grade, stage, surgery, radiotherapy, chemotherapy, aromatase inhibitor (as time varying covariate), tamoxifen (as time varying covariate), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin usage (as time varying covariate). Analyses were conducted by number of tablets dispensed and repeated for all-cause mortality. Subgroup analyses were conducted by cancer stage, year of diagnosis and oestrogen receptor status. Separate sensitivity analysis was conducted by additionally adjusting for tumour hormone receptor status, broadening the definition of breast cancer-specific death (i.e. if C50 was listed as any cause of death on death certificates) and increasing the lag from six months to 1 year, thereby excluding prescriptions in the year prior to death. A simplified analysis was conducted using Cox regression to compare low-dose aspirin users to non-users in the first year after breast cancer diagnosis in individuals living more than 1 year after diagnosis; this controls immortal time bias [29] without requiring time varying covariates. An analysis was conducted based upon low-dose aspirin prescriptions in the year prior to diagnosis (excluding patients diagnosed in 2009 for whom a full year of prescription records prior to diagnosis may not be available), not excluding deaths in the first year after diagnosis. An adjusted analysis for pre-diagnostic low-dose aspirin use was first conducted omitting stage, grade, cancer treatment from adjustments for potential confounders to avoid over-adjustment [30, 31] , as these could be on the causal pathway for breast cancerspecific mortality. Similar sensitivity analyses were carried out for all-cause mortality. As low-dose aspirin is primarily indicated for the primary and secondary prevention of cardiovascular disease, further analyses was conducted for only cardiovascular deaths (where the underlying cause of death was ICD 10 codes I0-99, G45, Q20-26, F01 or equivalent ICD-9 codes) and for all deaths excluding these cardiovascular deaths.
RESULTS
Patient cohort
A total of 15,140 newly diagnosed breast cancer patients met the inclusion criteria, in which there was on average 4 years of follow-up after diagnosis (sd=1, minimum=1, maximum=6 years). Patient characteristics by post-diagnostic low-dose aspirin use are shown in Table 1 .
Low-dose aspirin users were more likely to be older and to be from deprived areas.
Compared to non-users, a slightly smaller proportion of low-dose aspirin users were diagnosed with early stage tumours (34.6% versus 40.1%, respectively) while a slightly larger proportion of users were diagnosed with poorly differentiated tumours (29.3% versus 35.7%, respectively). Low-dose aspirin users were less likely to receive cancer treatments (including surgery, chemotherapy and tamoxifen); however they were more likely to receive aromatase inhibitors. A greater proportion of low-dose aspirin users compared to non-users had comorbidities (particularly for cerebrovascular disease, diabetes and myocardial infarction) and were users of statins.
Association between low-dose aspirin use after diagnosis and survival
The main findings are displayed in Table 2 . Low-dose aspirin use after diagnosis was associated with an increase in breast cancer-specific mortality (HR 1.44, 95% CI 1.26, 1.65); however after adjusting for age at diagnosis results attenuated to the null (age adjusted HR 1.03, 0.88, 1.18). After adjustment for potential confounders the HR was 0.92 (95% CI 0.75, 1.14), Table 2 . No significant duration-response association was observed when exposure was investigated by increasing number of tablets. There was a suggestion of a significant reduction in breast cancer mortality risk with the use of 730-1,095 aspirin tablets (adjusted HR 0.55, 95% CI 0.32, 0.96); however, the increasing duration of use analysis did not follow a clear pattern and the reduction in breast cancer mortality risk was not observed for users of 1,095+ tablets (adjusted HR 1.22, 95% CI 0.75, 2.00).
Similarly, post-diagnostic low-dose aspirin use was associated with an increase in all-cause mortality (HR 2.18, 95% CI 1.99, 2.40) which weakened in adjusted analysis but remained statistically significant (adjusted HR 1.21 1.04, 1.40). In duration-response analysis, a 26% increased risk of death was seen for users of 1-365 tablets after diagnosis, however results attenuated and became non-significant among users of , 365-730 tablets and 730-1,095 tablets, Table 2 . For users of 1,095 tablets (i.e. more than 3 years of use), a significant increase in breast cancer mortality was observed (adjusted HR 1.44, 95% CI 1.03, 2.03). . Table 4 ) suggested that the increase in all-cause mortality observed for low-dose aspirin users was largely due to cardiovascular deaths (adjusted HR 1.73, 95 % CI 1.19, 2.50) and once these deaths were removed, there was no increase in allcause mortality in users compared to non-users (adjusted HR 1.11; 95 % CI 0.94-1.31).
Further analyses (shown in
Association between low-dose aspirin use before diagnosis and survival
Results for low-dose aspirin use in the year preceding diagnosis are shown in Table 3 . In adjusted models, there was little evidence of an association between low-dose aspirin use before diagnosis and cancer-specific mortality (adjusted HR 0.95, 85% CI 0.81, 1.11). For all-cause mortality, a significant increase in risk was observed for low-dose aspirin users before diagnosis (HR 2.33, 95% CI 2.12, 2.56). Table 4 summarises results for sensitivity\secondary analyses. In comparison to the main analysis, stratification by cancer stage, year of diagnosis and hormone receptor status did not materially alter associations between post-diagnostic low-dose aspirin use after diagnosis and cancer-specific mortality. Similar effect estimates were observed after additional adjustment for ER, PR and HER2 status, after broadening the definition of breast cancer-specific death, as well as in analysis increasing the lag to 1 year. In the simple analysis, low-dose aspirin use compared to non-use in the year after diagnosis was not associated with cancer-specific mortality, Table 4 . For all-cause mortality, similar to the main analysis, an increase in breast cancer mortality risk was observed for post-diagnostic low-dose aspirin use across sub-group and sensitivity analyses, however; as described earlier, this is likely driven by cardiovascular deaths, Table 4 .
Sensitivity\secondary analyses for low-dose aspirin use after diagnosis and survival
DISCUSSION
Our study, which utilised prospectively recorded information from national cancer, death and drug dispensing registries, found little evidence of an association between the use of low-dose aspirin after diagnosis and breast cancer-specific mortality. We did not observe any clear relationship by increasing duration of use and results were similar across a number of subgroup and sensitivity analyses.
Our results are contrary to some, but not all previous epidemiological studies of postdiagnostic aspirin use and breast cancer-specific survival. Data from two American cohorts, the Nurses' Health Study [10] and the Iowa Women's Health Study [9] reported substantial reductions in breast cancer mortality in users of aspirin after diagnosis compared to nonusers. These studies restricted their cohorts to patients diagnosed with early stage breast cancer and obtained information on aspirin exposure through questionnaires. Hence, differences in patient populations and study methodologies make comparisons with our findings difficult. Moreover, there was a lack of information on aspirin dose used in these studies although high-dose aspirin is more commonly used in the USA in comparison to the UK [32] . It is possible that the extended breast cancer survival observed for aspirin users in these studies may be due to higher PTSG-2 inhibiting doses as opposed to doses which inhibit platelet function. Our study also contradicts the results from a recent Scottish study which observed an approximate 60% reduction in cancer mortality among users of low-dose aspirin use after diagnosis (adjusted HR 0.42, 95% CI 0.31, 0.55) [11] . Like ours, this study utilised linked cancer registration and dispensed medication data, but their findings may have partly been affected by reverse causation as they utilised an unlagged start/stop time-varying covariate approach which allocated cancer-specific deaths to the aspirin user or nonuser group on the basis of whether they had an aspirin prescription that covered the time of death.
As such, if clinicians discontinued aspirin medication in patients suspected of imminent death, the use of unlagged time-varying covariates could potentially bias results making aspirin appear spuriously protective [12] . In our analysis, we lagged medication use after diagnosis by 6 months and this period was varied in sensitivity analysis. Other epidemiological studies have reported no association for aspirin use after diagnosis and risk of breast cancer death [15, 16, 17] . Similar to our investigation, these studies assessed the impact of low-dose aspirin specifically and drug use was captured using population-based prescribing databases. We found that low-dose aspirin use after diagnosis was associated with a slight increase in all-cause mortality risk but the findings may reflect risk of death from other (non-cancer) causes, as suggested by the observed increase in cardiovascular deaths in users of low-dose aspirin.
In secondary analysis, we did not observe an association between aspirin use in the year prior to diagnosis and breast cancer-specific mortality, which is in agreement with a previous large population-based study we conducted within the Clinical Practice Research Datalink (CPRD) [15] . In contrast, in a cohort of stage I-III patients diagnosed in Ireland, aspirin use (predominantly low-dose) in the year prior to diagnosis was associated with a weak nonsignificant reduction in breast cancer mortality (HR 0.80, 95% CI 0.62, 1.04) [33] . In a further study of 935 breast cancer patients enrolled in the Carolina Breast Cancer Study, increased duration and regularity of self-reported pre-diagnostic NSAID use (including aspirin) was associated with reduced breast cancer-specific mortality in women with ERpositive tumours while no association was seen for women with ER-negative tumours [34] .
The authors of this study however did not examine the influence of aspirin separately. The potential anti-cancer effect of aspirin has been hypothesised to be, in part, mediated through suppression of oestrogen biosynthesis [35, 36] , but similar to our study, two previous cohort studies found no difference in associations by hormone receptor status [10, 17] .
Strengths of this study included the utilisation of an unselected population-wide cohort of breast cancer patients identified from national cancer registries, therefore allowing for robust verification of breast cancer cases. Prospective national prescribing databases were used to objectively ascertain aspirin use and avoid potential for recall bias incurred by self-report. It also facilitated detailed examination of the timing of aspirin use, as well as the conduct of duration-response analyses. Misclassification of drug use is possible as over-the-counter use of low-dose aspirin was not accounted for, although previous evidence suggests that the majority of chronic aspirin use in administrative prescribing databases is captured [37] . In Scotland specifically, long-term aspirin use has been shown to be primarily prescriptionbased [38] . Some misclassification of breast cancer deaths may have occurred, however methodological studies have suggested that in comparative studies where differential misclassification of death is unlikely, as in our study, effect estimates are unlikely to be affected [39] . Confounding by indication, often a problem in pharmacoepidemiology, is unlikely to have influenced our main finding for breast cancer-specific mortality, but would explain the small increases in all-cause mortality primarily due to raised cardiovascular mortality in low-dose aspirin users. Finally, we did not have information on drug adherence but similar associations were observed among patients who received multiple prescriptions in whom adherence may be more likely.
Conclusion
In this large nation-wide cohort of breast cancer patients, we found little evidence of a reduction in cancer-specific mortality with the use of low-dose aspirin after diagnosis. The recently opened 'Add Aspirin' trial will investigate the influence of low dose aspirin (100mg and 300mg) in early stage cancer patients (including breast) and will provide additional insight into the potential role of aspirin in the adjunct cancer setting [40] . Further, large-scale, rigorously designed observational studies of aspirin in breast cancer progression are warranted however, as the results from this trial are not due until 2020.
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